As recent studies suggest, inhibiting PARP-1 in models of CNS injury, including traumatic brain injury and spinal cord injury, has demonstrated therapeutic promise by mitigating cellular damage and promoting tissue preservation (Berger et al., 2017). The gene discussed is PARP1; the disease is injury.